EP 1047691 A1 20001102 - QUINOLINEPIPERAZINE AND QUINOLINEPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS COMBINED 5-HT1A, 5-HT1B AND 5-HT1D RECEPTOR ANTAGONISTS
Title (en)
QUINOLINEPIPERAZINE AND QUINOLINEPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS COMBINED 5-HT1A, 5-HT1B AND 5-HT1D RECEPTOR ANTAGONISTS
Title (de)
CHINOLINPIPERAZIN- UND CHINOLINPIPERIDIN DERIVATE, DEREN HERSTELLUNG UND DEREN VERWENDUNG ALS KOMBINIERTE 5-HT1A, 5-HT1B UND 5-HT1D REZEPTOR ANTAGONISTEN
Title (fr)
DERIVES DE QUINOLEINEPIPERAZINE ET DE QUINOLEINEPIPERIDINE, LEUR PREPARATION ET LEUR UTILISATION EN TANT QU'ANTAGONISTES COMBINES DES RECEPTEURS 5-HT1A, 5-HT1B ET 5-HT1D
Publication
Application
Priority
- EP 9807804 W 19981202
- GB 9726364 A 19971212
- GB 9726905 A 19971219
- GB 9800317 A 19980107
Abstract (en)
[origin: WO9931086A1] The invention relates to compounds of formula (I) or a salt thereof in which R<a> is selected from a group of formula (i), (ii) or (iii); L is a group of formula -Y-C(=O)-DG- or -C(=O)-DG- or -DG-C(=O)- in which Y is -NH-, NR<5> where R<5> is C1-6alkyl, or Y is -CH2- or -O-; D is nitrogen, carbon or a CH group, or G is hydrogen or C1-6alkyl providing that D is nitrogen or a CH group, or G together with R<b1> forms a group W where W is (CR<16>R<17>)t where t is 2, 3 or 4 and R<16> and R<17> are independently hydrogen or C1-6alkyl or W is (CR<16>R<17>)u-J where u is 0, 1, 2 or 3 and J is oxygen, sulphur, CR<16>=CR<17>, CR<16>=N, =CR<16>O, =CR<16>S or =CR<16>-NR<17> provided that u is not 0 when J is oxygen or sulphur; X is nitrogen or carbon; R<b1>, R<b2> and R<b3> are independently hydrogen, halogen, hydroxy, C1-6alkyl, C2-6alkenyl, C3-6cycloalkyl, trifluoromethyl, C1-6alkoxy or aryl, or R<b1> together with G forms a group W as defined above; R<c> is hydrogen or C1-6alkyl; and <o>-------</o> is a single bond when X is nitrogen or a single or double bond when X is carbon; having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders.
IPC 1-7
C07D 401/12; A61K 31/47; C07D 215/42; C07D 215/46; C07D 413/12; A61K 31/505; C07D 471/04
IPC 8 full level
C07D 215/42 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61P 25/00 (2006.01); A61P 25/24 (2006.01); A61P 43/00 (2006.01); C07D 215/46 (2006.01); C07D 401/12 (2006.01); C07D 413/12 (2006.01); C07D 471/04 (2006.01)
CPC (source: EP)
A61P 25/00 (2017.12); A61P 25/24 (2017.12); A61P 43/00 (2017.12); C07D 215/46 (2013.01); C07D 401/12 (2013.01); C07D 413/12 (2013.01); C07D 471/04 (2013.01)
Citation (search report)
See references of WO 9931086A1
Designated contracting state (EPC)
BE CH DE ES FR GB IT LI NL
DOCDB simple family (publication)
WO 9931086 A1 19990624; CA 2313125 A1 19990624; EP 1047691 A1 20001102; JP 2002508366 A 20020319
DOCDB simple family (application)
EP 9807804 W 19981202; CA 2313125 A 19981202; EP 98965729 A 19981202; JP 2000539010 A 19981202